Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
AssigneeIcahn School of Medicine at Mount Sinai
InventorsWillem Mulder, Jordi Ochando, Zahi Fayad, Mounia Braza, Raphaël Duivenvoorden, Francois Fay
Life of this patent
Estimating the term…
Abstract
Methods and compositions for inducing long-term tolerance by hybrid nanoparticles are provided. Compositions and formulations comprising hybrid nanoparticles with inherent affinity for innate immune cells are provided.
Claims18
A method for reducing tissue rejection in a patient in need thereof, the method comprising administering to the patient an effective amount of a composition comprising a high-density lipoprotein (HDL)-derived nanoparticle which comprises an mTOR inhibitor selected from rapamycin or an ester or prodrug thereof, a phospholipid, and an apolipoprotein A-I (apoA-I), wherein the patient has received an allogeneic tissue transplant, and wherein the composition is administered intravenously.
A method for the prophylaxis of tissue rejection in a patient in need thereof, the method comprising administering to the patient an effective amount of a composition comprising a high-density lipoprotein (HDL)-derived nanoparticle which comprises an mTOR inhibitor selected from rapamycin or an ester or prodrug thereof, a phospholipid, and an apolipoprotein A-I (apoA-I)), and wherein the composition is administered intravenously.
Dependencies are inferred from the claim text.